Concizumab
Haemophilia A, Haemophilia B
Novo Nordisk A/Smonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Haemophilia A, Haemophilia B cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Concizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →